Gilliland Taylor M, Villafane-Ferriol Nicole, Shah Kevin P, Shah Rohan M, Tran Cao Hop S, Massarweh Nader N, Silberfein Eric J, Choi Eugene A, Hsu Cary, McElhany Amy L, Barakat Omar, Fisher William, Van Buren George
The Elkins Pancreas Center, Michael E. DeBakey Department of Surgery, and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Nutrients. 2017 Mar 7;9(3):243. doi: 10.3390/nu9030243.
Pancreatic cancer is an aggressive malignancy with a poor prognosis. The disease and its treatment can cause significant nutritional impairments that often adversely impact patient quality of life (QOL). The pancreas has both exocrine and endocrine functions and, in the setting of cancer, both systems may be affected. Pancreatic exocrine insufficiency (PEI) manifests as weight loss and steatorrhea, while endocrine insufficiency may result in diabetes mellitus. Surgical resection, a central component of pancreatic cancer treatment, may induce or exacerbate these dysfunctions. Nutritional and metabolic dysfunctions in patients with pancreatic cancer lack characterization, and few guidelines exist for nutritional support in patients after surgical resection. We reviewed publications from the past two decades (1995-2016) addressing the nutritional and metabolic status of patients with pancreatic cancer, grouping them into status at the time of diagnosis, status at the time of resection, and status of nutritional support throughout the diagnosis and treatment of pancreatic cancer. Here, we summarize the results of these investigations and evaluate the effectiveness of various types of nutritional support in patients after pancreatectomy for pancreatic adenocarcinoma (PDAC). We outline the following conservative perioperative strategies to optimize patient outcomes and guide the care of these patients: (1) patients with albumin < 2.5 mg/dL or weight loss > 10% should postpone surgery and begin aggressive nutrition supplementation; (2) patients with albumin < 3 mg/dL or weight loss between 5% and 10% should have nutrition supplementation prior to surgery; (3) enteral nutrition (EN) should be preferred as a nutritional intervention over total parenteral nutrition (TPN) postoperatively; and, (4) a multidisciplinary approach should be used to allow for early detection of symptoms of endocrine and exocrine pancreatic insufficiency alongside implementation of appropriate treatment to improve the patient's quality of life.
胰腺癌是一种侵袭性恶性肿瘤,预后较差。该疾病及其治疗会导致严重的营养障碍,常常对患者的生活质量(QOL)产生不利影响。胰腺具有外分泌和内分泌功能,在癌症情况下,这两个系统都可能受到影响。胰腺外分泌功能不全(PEI)表现为体重减轻和脂肪泻,而内分泌功能不全可能导致糖尿病。手术切除是胰腺癌治疗的核心组成部分,可能会诱发或加剧这些功能障碍。胰腺癌患者的营养和代谢功能障碍缺乏特征描述,术后营养支持的指南也很少。我们回顾了过去二十年(1995 - 2016年)关于胰腺癌患者营养和代谢状况的出版物,将它们分为诊断时的状况、切除时的状况以及胰腺癌诊断和治疗全过程中的营养支持状况。在此,我们总结这些研究结果,并评估胰腺癌根治术(PDAC)后患者不同类型营养支持的效果。我们概述以下围手术期保守策略,以优化患者预后并指导这些患者的护理:(1)白蛋白<2.5 mg/dL或体重减轻>10%的患者应推迟手术并开始积极的营养补充;(2)白蛋白<3 mg/dL或体重减轻5%至10%的患者应在手术前进行营养补充;(3)术后营养干预应优先选择肠内营养(EN)而非全肠外营养(TPN);(4)应采用多学科方法,以便早期发现胰腺内分泌和外分泌功能不全症状,并同时实施适当治疗以改善患者生活质量。